A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum Based Chemotherapy

Disease Sites:

Gynecologic, Ovarian

Staging:

Phase III

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Bevacizumab, Olaparib

Principal Investigator(s):

Crispens, Marta

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

06-19-2025

Trial Type:

Treatment

Protocol ID:

NRGGYNGY036

National Clinical Trial ID:

NCT06580314

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available